Selank is a synthetic heptapeptide and tuftsin analog with the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It has been investigated in experimental research involving neurobiology, GABAergic signaling, BDNF expression, stress-response models, immune-related signaling, and peptide structure-function relationships. Helix Bio offers Selank as a research-use-only peptide for qualified laboratory and non-clinical research. It is not intended for human consumption, self-administration, diagnosis, treatment, cure, or prevention of any disease or medical condition.
HPLC certified
Independent analysis
Highest standard
Full traceability
Selank is a synthetic heptapeptide derived from the structure of tuftsin, an endogenous tetrapeptide. Its commonly reported amino acid sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro.
The compound has been investigated primarily in Russian scientific research and literature covering neuropharmacology, stress-response models, GABAergic signaling, neurotrophic pathways, and immune-related research. Research has examined several possible biological mechanisms rather than establishing one definitive mechanism of action, investigating Selank's relationship with GABA receptor signaling, enkephalin-degrading enzymes, BDNF expression, and gene-expression changes associated with neurotransmission.
For laboratory researchers, Selank provides a defined peptide model for studying how a synthetic tuftsin analog interacts with molecular and cellular pathways.
Selank is a seven-residue peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro), commonly described as a tuftsin analog because its structure is based on the endogenous peptide tuftsin. Important research terminology associated with Selank includes heptapeptide, tuftsin analog, synthetic peptide, peptide bond, amino acid sequence, molecular mass, lyophilized peptide, peptide degradation, and analytical characterization.
There is no single mechanism that adequately describes every experimental observation involving Selank. Research has explored several possible pathways: GABAergic signaling, enkephalin metabolism, BDNF expression, neurotransmission-related gene expression, opioid-system interactions, stress-response signaling, and immune and cytokine-related responses.
A 2018 review described research suggesting that Selank may interact with GABAergic signaling through allosteric modulation of GABA receptors. Separate research in rats found changes in the expression of multiple genes involved in neurotransmission following Selank exposure, with the authors proposing that GABAergic signaling may represent one component of its molecular activity. These findings remain experimental and should not be converted into claims about therapeutic efficacy or human outcomes.
The GABAergic system is one of the better-known molecular research areas associated with Selank. A study examining Selank's molecular activity reported changes involving GABA receptor binding and proposed subtype-selective, concentration-dependent allosteric modulation as one possible mechanism. Another study analyzed the expression of genes involved in GABAergic neurotransmission in rat frontal cortex and observed changes in numerous neurotransmission-related genes after experimental Selank exposure. A separate cell-culture study produced a more nuanced result: Selank did not directly change the mRNA levels of the GABAergic genes examined in IMR-32 neuroblastoma cells, although the findings partially supported a possible interaction with GABA receptor signaling. Research results can depend on the species, tissue, cell type, experimental conditions, exposure parameters, and analytical method.
Another proposed mechanism concerns enkephalin metabolism. A PubMed-indexed study investigated Selank's ability to inhibit enzymes involved in enkephalin degradation, reporting concentration-dependent inhibition of enkephalin hydrolysis and proposing that this pathway could contribute to the compound's observed experimental effects. This makes Selank relevant to research examining enkephalin metabolism, peptidase activity, opioid-related signaling, peptide degradation pathways, and neurochemical regulation. The findings should be considered mechanistic research rather than evidence of a medical benefit.
Brain-derived neurotrophic factor (BDNF) is another area of interest in Selank research. Experimental studies have investigated Selank-associated changes in BDNF expression in brain regions including the hippocampus. One study reported that intranasal administration of Selank regulated BDNF expression in the rat hippocampus, and another animal study examined Selank and BDNF content in the hippocampus and prefrontal cortex in a rat model involving chronic ethanol exposure. The evidence is experimental and should not be interpreted as establishing human cognitive or therapeutic effects.
Researchers evaluating a Selank peptide supplier should consider more than the product name or stated purity percentage. For reproducible research, the material should be identifiable and traceable to a specific batch. Analytical documentation can help researchers evaluate peptide identity, reported purity, batch number, molecular-mass confirmation, chromatographic profile, storage requirements, and product handling information.
Helix Bio's product and quality claims are presented only according to the current documentation actually available for the specific Selank batch — a specific purity percentage, third-party testing claim, certification, or COA result is only published when supported by current batch documentation.
Selank is not intended for human consumption, self-administration, injection, or veterinary use.
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Cyclic peptides resist protease degradation and reach undruggable targets. Learn how peptide cyclization works and why stability improves. Explore the research.
How continuous flow, automation, enzymatic routes and AI are changing peptide synthesis technology, and what it means for research peptide purity and supply.
AI now designs peptides from scratch. How AlphaFold 3, RFdiffusion and protein language models reshaped peptide discovery in 2026 — research use only.
